Medical Device Coatings

Abstract

A coating for a medical device is described. The coating comprises a base layer comprising a protein, and a polymer layer disposed on the base layer. The polymer layer comprises a polymer having a plurality of hemocompatible groups. Each hemocompatible group is independently selected from sulfonic acid groups, sulfonamide groups, sulfamic acid groups, hydrogen sulfate groups, and their conjugate salts. Also described are medical devices comprising the coating, and uses and methods involving the coating and the medical device.

Description

[Technical field]

[0001] The present invention relates to a coating for a medical device. The present invention further relates to a medical device comprising the coating, and to uses and methods involving the coating or a medical device comprising the coating. The present invention also relates to a method for producing the coating and a kit for coating a medical device. [Background technology]

[0002] The formation of a blood clot in an organ or tissue can represent a potentially life-threatening condition. When using a medical device, blood may come into contact with the foreign surface of the device, which may induce the formation of a blood clot. Therefore, patients may be administered an anticoagulant before using the medical device to inhibit blood clotting and the formation of a blood clot. However, the administration of anticoagulants has significant side effects that must be considered. For some patients, it may not be safe to administer such an anticoagulant.

[0003] Some medical devices, such as stents, are coated with heparin, an anticoagulant that prevents the formation of blood clots. Heparin is a glycosaminoglycan. It is difficult to coat medical devices and relatively expensive. The use of heparin is also associated with several side effects, including bleeding, severe pain (e.g., at the injection site), nausea, and unusual fatigue. There are also serious side effects associated with the use of heparin, such as heparin-induced thrombocytopenia. Heparin is contraindicated in several conditions, including brain surgery, spinal surgery, eye surgery, hemophilia, anticoagulant deficiency, uncontrolled high blood pressure, subacute infection of the heart valve, intracerebral hemorrhage, dilation and tearing of the aortic vessel wall, stomach or intestinal ulcers, ulcerative colitis, intestinal inflammatory conditions, diverticulitis, severe liver disease, biliary and gallbladder problems, osteoporosis, and stage 4 (severe) or stage 5 (failure) chronic kidney disease.

[0004] Other types of coatings have also been applied to medical devices. These coatings typically include multifunctional polymerizable compounds. The problem with such coatings is that they have poor coating performance and degrade after a relatively short period of time. If the coating lacks mechanical robustness, degradation by-products can leach into the patient, which may be undesirable for some coatings. Summary of the Invention

[0005] The present invention provides a coating for a medical device comprising a polymer layer, the polymer layer comprising a polymer having a plurality of hemocompatible groups, each hemocompatible group independently selected from sulfonic acid groups, sulfonamide groups, sulfamic acid groups, hydrogen sulfate groups, and their conjugate salts.

[0006] Typically, the coating further comprises a base layer, and the polymer layer is disposed on the base layer. The base layer typically comprises a protein.

[0007] The coating of the present invention is non-thrombogenic and blood compatible, and has a prophylactic effect in that it can prevent or inhibit the formation of thrombi, and thus prevent or inhibit the onset, progression or recurrence of thrombus-related diseases and conditions.

[0008] The present inventors have discovered polymeric materials that have advantageous properties for use as coatings for medical devices, especially when they contain hemocompatible groups. Hemocompatible groups are also referred to herein as antithrombogenic groups (i.e., the term "hemocompatible groups" is synonymous with "antithrombogenic groups"). Hemocompatible groups contribute to the overall hemocompatibility of the coating.

[0009] The present invention also provides a method of producing a coating for a medical device. The method includes (a) applying a polymer having a plurality of hemocompatible groups as described herein onto a base layer to form a polymer layer. Each hemocompatible group may be independently selected from sulfonic acid groups, sulfonamide groups, sulfamic acid groups, hydrogen sulfate groups, and their conjugate bases. The base layer typically includes a protein.

[0010] The present invention further relates to coatings obtained or obtainable from the methods for producing coatings described herein.

[0011] The present invention also provides a medical device having a surface coated with a coating as described herein.

[0012] The present invention may further provide a method of coating a surface of a medical device.A method of producing a coating for a medical device may include a method of coating a surface of a medical device.

[0013] A further aspect of the present invention relates to a kit for coating a medical device. The kit comprises: (a) a polymer having a plurality of hemocompatible groups as described herein; (b) a base coating solution; and (c) a coupling agent. Each hemocompatible group is independently selected from sulfonic acid groups, sulfonamide groups, sulfamic acid groups, hydrogen sulfate groups, and their conjugate bases. The base coating solution typically includes a protein.

[0014] The present invention further relates to the use of coatings and medical devices.

[0015] The coating of the invention or the medical device of the invention may be used in the treatment of the human or animal body by surgery or therapy and / or in diagnostic methods performed on the human or animal body. Diagnostic methods performed on the human or animal body are typically in vivo diagnostic methods.

[0016] The coating of the invention or the medical device of the invention is for use in reducing or preventing blood clotting.

[0017] The present invention also provides a method of reducing or preventing blood clotting, the method comprising contacting a medical device of the present invention with blood.

[0018] One embodiment of the method of the present invention may be an in vitro method of reducing or preventing blood clotting, such as when treating blood. The method may include contacting a medical device with blood, the blood being removed from a human or animal body. The blood may be contacted with the medical device to treat the blood. The treated blood may not be returned to the human or animal body, preferably the human or animal body from which the blood was removed.

[0019] Another aspect of the method of the present invention is a method of reducing or preventing blood clotting in a diagnostic procedure, which may include contacting a medical device with blood to obtain diagnostic information.

[0020] (definition) The term "biocompatibility" as used herein, particularly in the context of a coating or a component thereof, refers to the ability of a medical device or material to function with an appropriate host response in a particular application (e.g., as defined in ISO 10993-1 (2018)). The definition of "biocompatibility" in ISO 10993-1 (2018), its related terms, and tests for its evaluation are incorporated herein by reference. In general terms, biocompatibility refers to the ability of a medical device or material to perform its desired function in relation to a medical therapy, generating the most appropriate beneficial cellular or tissue response in that particular context, and optimizing the clinically relevant performance of that therapy, without inducing undesirable local or systemic effects in the recipient or beneficiary of that therapy.

[0021] As used herein, the term "alkyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms and containing no unsaturation. 1~6 An "alkyl" group contains 1 to 6 carbon atoms. Unless otherwise specified in the specification, an alkyl group is unsubstituted or can be substituted with hydroxy, C 1~6 It may be substituted with one or more substituents selected from alkoxy and halo (eg fluoro, chloro, bromo or iodo), preferably fluoro. Preferably, the alkyl group is unsubstituted.

[0022] As used herein, the term "alkoxy" refers to a group attached through an oxygen atom of the formula --O-alkyl, where alkyl is defined above.

[0023] The term "aryl" as used herein refers to a group derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing hydrogen atoms from ring carbon atoms. An aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon atoms, and at least one of the rings in the ring system is fully unsaturated (i.e., contains a cyclic delocalized [4n+2] π-electron system according to the Hückel theory). Ring systems from which aryl groups can be derived include, for example, benzene, indane, indene, tetralin and naphthalene.

[0024] The term "arylalkyl" as used herein refers to a group bonded to an alkyl group as defined above, which is further substituted by (or bonded to) an aryl group as defined above. Examples of arylalkyl groups include benzyl (PhCH2-) and phenylethyl. The benzyl group is an example of a C6 aryl-C1 alkyl group.

[0025] As used herein, the term "alkylene" refers to a straight or branched divalent hydrocarbon chain consisting of carbon and hydrogen atoms and containing no unsaturation. Examples of preferred alkylene groups include -CH-, -CH-CH-, CHCH-CH-, CH(CH)-, and -C(CH)-CH-. 1~10 The "alkylene" group contains 1 to 10 carbon atoms.

[0026] The term "alkenylene" as used herein refers to a straight or branched divalent hydrocarbon chain consisting of carbon and hydrogen atoms and containing at least one double bond. The alkene group may have a cis or trans configuration. Exemplary alkenylene groups include -CH=CH-, -CH2-CH=CH-, C(CH3)=CH-CH2-, CH2C(CH3)=CH-CH2-, and -CH2CH=C=CH-CH2-. "C 2~10 An alkenylene group contains 2 to 10 carbon atoms. When the alkenylene contains more than one double bond, the double bonds may be conjugated or non-conjugated. It is preferred that the alkenylene group does not contain an allene group. More preferably, it is preferred that the alkenylene group contains a single double bond.

[0027] The term "alkene" as used herein refers to a straight or branched hydrocarbon chain radical group consisting of carbon and hydrogen atoms and containing at least one carbon-carbon double bond.

[0028] The term "alkynylene" as used herein refers to a straight or branched divalent hydrocarbon chain consisting of carbon and hydrogen atoms and containing at least a triple bond. Examples of alkylene groups include -C≡C-, -CH2-C≡C-, -CH(CH3)-C≡C-CH2-, and -CH2-C≡C-C≡C-C(CH3)=CH-CH2-. 2~10An alkynylene group contains 2 to 10 carbon atoms. When the alkynylene group contains more than one triple bond, the triple bonds may be conjugated or non-conjugated. Preferably, the alkynylene group does not contain a double bond (e.g., a carbon-carbon double bond). More preferably, the alkynylene group contains a single triple bond.

[0029] As used herein, the term "phenylene" refers to a divalent group derived from benzene (e.g., -CH-). A divalent group (e.g., a disubstituted benzene ring) may have ortho-, meta- or para-configuration of the substituents.

[0030] Unless otherwise specified in the specification, each of the aforementioned groups (eg, alkyl, alkene, alkoxy, aryl, arylalkyl, alkylene, alkenylene, alkynylene, phenylene) is unsubstituted.

[0031] Unless expressly stated to the contrary, reference to a formula of a repeat unit, monomer or polymer (e.g., the terms "a repeat unit of formula (A-1)", "a repeat unit of formula (B-1)", "a monomer of formula (a-1)" or "a monomer of formula (b-1)") should be understood to include any and all repeat units, monomers or polymers described by and / or with reference to the formula, respectively. These terms should also be understood to encompass all stereoisomers, particularly cis- and trans-isomers, and optical isomers, i.e., R and S enantiomers, of such repeat units, monomers or polymers, either in substantially pure form or as mixtures of stereoisomers and / or optical isomers.

[0032] As used in this disclosure, the term "comprises" has an open meaning that allows for other, unspecified features to be present. This term encompasses, but is not limited to, the semi-closed term "consisting essentially of" and the closed term "consisting of." Unless the context indicates otherwise, the term "comprising" can be replaced with either "consisting essentially of" or "consisting of." Also, the term "consisting essentially of" can be replaced with "consisting of." DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] The present invention provides a coating for a medical device. The coating reduces or prevents blood clotting. The coating is typically an antithrombotic coating, such as an anticoagulant coating and / or an antiplatelet coating, preferably an antiplatelet coating. The coating is typically a hemocompatible coating.

[0034] As used herein, reference to "blood" generally refers to the blood of a human or non-human animal, such as a mammal. The present invention can also be used in veterinary applications. The term "blood" preferably refers to human blood.

[0035] Generally, the coating is biocompatible, and preferably biocompatible and / or hemocompatible.

[0036] Generally, the coating comprises a surface layer. The surface layer is the top layer of the coating. Thus, the surface layer may be the outer surface layer of the coating or coated medical device. During use, the surface layer of the coating is in contact with blood.

[0037] The surface layer or coating (eg as a whole) may be in the form of a gel, preferably a hydrogel, which can provide a lubricious surface to the medical device.

[0038] Generally, the surface layer is biocompatible.

[0039] The surface layer may comprise or consist essentially of a polymer having multiple hemocompatible groups, as described herein. If the coating comprises a total of two layers, the surface layer is the polymer layer.

[0040] Each hemocompatible group is selected from sulfonic acid, sulfonamide, sulfamic acid, hydrogen sulfate and their conjugate bases. The structure of each group is shown below with a wavy line indicating the point of attachment of the group directly or indirectly to the polymer. TIFF2024520221000001.tif31135

[0041] Generally, it is preferred that each hemocompatible group is independently selected from sulfonic acid groups, sulfamic acid groups, hydrogen sulfate groups, and their conjugate bases, and more preferably, each hemocompatible group is independently selected from sulfonic acid groups or sulfonate groups (i.e., the conjugate bases of sulfonic acid groups).

[0042] The conjugate base of each group is shown below. The conjugate base of each group means a sulfonate group, a sulfonamide anion group, a sulfamate group, or a sulfate group, respectively. TIFF2024520221000002.tif41149

[0043] The multiple blood compatible groups are preferably the same blood compatible group and / or their conjugate bases.

[0044] Typically, the plurality of blood-compatible groups is selected from sulfonic acid groups or their conjugate bases, sulfonamide groups or their conjugate bases, sulfamic acid groups or their conjugate bases, and hydrogen sulfate groups or their conjugate bases. More preferably, the plurality of blood-compatible groups is selected from sulfonic acid groups or sulfonate groups (i.e., conjugate bases of sulfonic acid groups).

[0045] Without wishing to be bound by theory, it is believed that when the blood compatibility groups described herein are ionized, the negatively charged conjugate base (such as a sulfonic acid group) repels platelet adhesion, thereby inhibiting or preventing the formation of thrombi on the surface of the coating. The examples in International Patent Application PCT / EP2020 / 081383, incorporated herein by reference, show that the blood compatibility groups (referred to as anticoagulant groups in the International Patent Application) have the activity of reducing or preventing thrombi. The polymers of the present invention may provide a high density of blood compatibility groups due to the relatively small molecular size of the repeating units.

[0046] The polymer comprising a plurality of blood compatible groups has a polymer chain. The polymer chain is the backbone of the polymer. It is preferred that the polymer chain is biocompatible.

[0047] Generally, each blood compatible group is attached to the polymer chain by a linker group, and thus the polymer contains multiple linker groups.

[0048] In principle, any linker group may be used to connect the hemocompatible group to the polymer chain, however, certain linker groups may provide or contribute to advantageous properties of the coating.

[0049] It is believed that the linker group should be relatively short (e.g., 1-3 atoms long) so that the surface of the coating presents a high negative charge density to the platelets. If a longer linker group is used, the coating surface may have a disordered arrangement of the hemocompatible groups due to the structural flexibility of the linker group. This can reduce the negative charge density provided by the surface of the coating.

[0050] In general, it is preferred that the linker group be biocompatible.

[0051] Each linker group covalently attaches a hemocompatible group to a polymer chain, and thus the linker group may have a first end that is covalently attached to the polymer chain and a second end that is covalently attached to the hemocompatible group.

[0052] A single blood compatible group may be attached to the polymer chain by a single linker group.

[0053] The polymer chain may be a linear polymer chain or a branched polymer chain, and is preferably a linear polymer chain.

[0054] The polymer or polymer chain typically has a number average (e.g., mean) molecular weight (Mn) of at least 300 g / mol, for example 300 to 50,000 g / mol, preferably 500 to 30,000 g / mol, more preferably 1,000 to 10,000 g / mol. The number average (e.g., mean) molecular weight (Mn) can be determined by light scattering.

[0055] The polymer having multiple blood compatible groups has the formula (A-1): JPEG2024520221000003.jpg4696[where, R A H and C 1~6 alkyl, R B H and C 1~6 alkyl, X 1 is expressed by the formula (S-1): -Z 1 -L 1 -SO2-Y 1 (S-1) It is expressed as In formula (S-1), Z 1 are O, NH and NR 1 is selected from R 1 is C 1~6 Alkyl, C 6~10 Aryl and C 6~10 Aryl C 1~6 alkyl, Y 1 O - , OH, NH - and NH2, L 1 is expressed by the formula (L‐1): -P 1 -Q 1 -W 1 (L‐1) It is expressed as In formula (L-1), P 1 is a single bond, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 selected from alkynylene and phenylene; Q 1 is a single bond, O, NH, NR 2 and phenylene; W 1 is a single bond, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 selected from alkynylene and phenylene; R 2 is C 1~6 Alkyl, C 6~10 Aryl and C 6~10 Aryl C 1~6 alkyl.] It may contain a repeating unit represented by the following formula:

[0056] The repeating unit represented by formula (A-1) may be a first repeating unit.

[0057] For convenience, the term "first repeat unit", and in particular the reference to "first", is used as a label to distinguish this repeat unit from other types of repeat units. Use of this term does not require that a "first repeat unit" be present, for example when reference is made to a "second repeat unit" or a "third repeat unit", etc. The same applies to the terms "second repeat unit", "third repeat unit", etc.

[0058] The repeating unit represented by formula (A-1) above is obtained or can be obtained from monomers of formula (a-1) described herein, such as, for example, 2-acrylamido-2-methyl-1-propanesulfonic acid (AMPS), 3-(acryloyloxy)propane-1-sulfonic acid or 3-(methacryloyloxy)propane-1-sulfonic acid. These monomers are commercially available.

[0059] In formula (A-1), the moiety L 1 represents a linker group.

[0060] In general, any layer, such as a polymer layer and / or a surface layer, having a polymer comprising a repeat unit represented by formula (A-1) typically comprises a polymer composition having a distribution of polymer molecules, where each molecule of the polymer comprises repeat units (e.g., varying numbers) as represented by formula (A-1) as described herein.

[0061] The repeating unit represented by formula (A-1) can further be represented by the following formula (A-2): It can be represented as TIFF2024520221000004.tif41134.

[0062] In formula (A-2), n1 is an integer greater than 0, and R A , R B and X 1 Each of is as defined herein.

[0063] In formula (A-1) or formula (A-2), R A H and C 1~3 alkyl, preferably R A is selected from H and methyl. More preferably, R A is H.

[0064] In formula (A-1) or formula (A-2), R B H and C 1~3 alkyl, preferably RB is selected from H and methyl. More preferably, R B is H.

[0065] In the formula (A-1) or (A-2), Z 1 NR 1 If R 1 C 1~6 It is preferably alkyl, particularly methyl or ethyl.

[0066] Typically, in formula (A-1) or formula (A-2), Z 1 is preferably selected from O and NH. 1 may be O. More preferably, Z 1 is NH. Z 1 When is O or NH, the linker group is typically attached to the polymer chain by an ester or amide group, which are biocompatible groups. In particular, amide groups, as they are present in peptides, are biocompatible.

[0067] P 1 is typically a single bond, C 1~10 alkylene and phenylene; and W 1 is a single bond, C 1~10 More preferably, P is selected from alkylene and phenylene. 1 is a single bond and C 1~10 alkylene; and W 1 is a single bond and C 1~10 It may be selected from alkylene.

[0068] Or P 1 is C 1~10 Alkylene, C 2~10 Alkenylene and C 2~10 alkynylene; Q 1 are O, NH and NR 2 Selected from W 1 is a single bond. More preferably, Q 1is selected from O and NH. In this arrangement, the blood compatible group is a sulfamate group, a sulfate group or a conjugate base thereof.

[0069] Typically, L 1 For more information, see P 1 , Q 1 and W 1 It is preferable that at least one of the following is not a single bond.

[0070] Q 1 If is O, then generally P 1 It is preferable that Q is not a single bond. More preferably, Q 1 If is O, then P 1 C 1~10 It is preferably alkylene, and more preferably P 1 C 2~4 It is alkylene.

[0071] Q 1 is O and P 1 If is not a single bond, W 1 It may be preferred that Q is not a single bond. More preferably, Q 1 If is O, then P 1 C 1~10 Alkylene, W 1 C 1~10 It is preferably alkylene, and more preferably P 1 C 2~4 Alkylene, W 1 C 2~4 It is alkylene.

[0072] Q 1 When is phenylene, generally, P 1 is a single bond or C 1~10 Alkylene, W 1 is a single bond or C 1~10 It is preferably alkylene. More preferably, Q 1 When is phenylene, P 1 is a single bond or C 1~3 Alkylene, W 1 is a single bond or C 1~3It is preferably alkylene.

[0073] In general, P 1 C 1~10 Alkylene, C 2~10 Alkenylene and C 2~10 alkynylene; Q 1 is a single bond, and W 1 is preferably a single bond. More preferably, P 1 is C 1~10 Alkylene, especially C 2~6 Alkylene, e.g. C 2~5 More preferably, P 1 is butylene, propylene or ethylene, preferably iso-butylene.

[0074] P 1 is ethylene and Q 1 and W 1 When both are single bonds, the moiety represented by (S-1) can be formed from taurine.

[0075] The repeating unit represented by formula (A-1) or formula (A-2) may be anionic, for example, Y 1 O - or NH - When the polymer chain is anionic, Na + or K + may be present as a counter cation.

[0076] Y 1 O - , OH and NH2. More preferably, Y 1 O - and OH.

[0077] Typically, the integer represented by n1 is at least 5, and preferably at least 10. For example, n1 may be 5-500, such as 10-300, and more preferably 15-100.

[0078] The polymer having multiple blood compatible groups has the formula (B-1): TIFF2024520221000005.tif41145 [In the formula, R C H and C 1~6 alkyl, R D , H, C 1~6 Alkyl and -C(O)X 2 is selected from each X 2 are independently O, OH, and OR 3 , NH2, NHR 3 and N(R 3 ) 2; and Each R 3 independently, optionally substituted C 1~6 Alkyl, optionally substituted C 6~10 Aryl and optionally substituted C 6~10 Aryl C 1~6 alkyl.] It may contain a repeating unit represented by the following formula:

[0079] The designation "C(O)" represents a carbonyl group, i.e., C=O.

[0080] The repeating unit represented by formula (B-1) may be a second repeating unit.

[0081] The repeating unit represented by formula (B-1) above may be or can be obtained from a monomer of formula (b-1) or a monomer of formula (b-2) described herein, such as, for example, acrylic acid, methacrylic acid, an ester of acrylic acid, an ester of methacrylic acid, an amide of acrylic acid, an amide of methacrylic acid, maleic acid or its ester, an amide or its anhydride, or a maleimide. The ester of methacrylic acid may be 2-hydroxyethyl methacrylate (HEMA) or 2-hydroxypropyl methacrylate. These monomers are commercially available.

[0082] In general, any layer having a polymer comprising a repeat unit represented by formula (B-1), such as a polymer layer and / or a surface layer, typically comprises a polymer composition. A polymer composition has a distribution of polymer molecules, where each molecule of the polymer comprises (e.g., varying numbers of) repeat units represented by formula (B-1) as described herein.

[0083] The repeating unit represented by formula (B-1) can further be represented by the following formula (B-2): It may also be represented as TIFF2024520221000006.tif41147.

[0084] In formula (B-2), n2 is an integer greater than 0, and R C , R D and X 2 Each of is as defined herein.

[0085] In formula (B-1) or formula (B-2), R C is H and C 1~3 alkyl, preferably R C is selected from H and methyl.

[0086] R D H and C 1~6 When selected from alkyl, preferably R C is methyl.

[0087] R D Ga-C(O)X 2 When R C is hydrogen.

[0088] In formula (B-1) or formula (B-2), R D H, C 1~3 Alkyl and -C(O)X 2 Preferably, R D is H, methyl and -C(O)X 2 More preferably, R D is hydrogen or -C(O)X2 R D R may be hydrogen. D ‐C(O)X 2 may be also possible.

[0089] R D Ga-C(O)X 2 In the case where the repeating unit represented by formula (B-1) or formula (B-2) is X 2 Each X 2 may be the same or different. Each X 2 are preferably identical.

[0090] Generally, in formula (B-1) or formula (B-2), X 2 OR 3 , N.H.R. 3 or N(R 3 )2, then each R 3 are independently optionally substituted C 1~6 Alkyl, optionally substituted C 6~10 Aryl and optionally substituted C 6~10 Aryl-C 1~6 alkyl. Thus, each R 3 is unsubstituted C 1~6 Alkyl, substituted C 1~6 Alkyl, unsubstituted C 6~10 Aryl, Substituted C 6~10 Aryl, unsubstituted C 6~10 Aryl-C 1~6 Alkyl and Substituted C 6~10 Aryl-C 1~6 The radicals may be independently selected from alkyl.

[0091] C 1~6 Alkyl, C 6~10 Aryl and C 6~10 Aryl-C 1~6 Each alkyl is independently hydroxy, C 1~6 It may be optionally substituted with one or more substituents selected from alkoxy and halo.

[0092] Each R 3is independently a hydroxy-substituted C 2~6 Alkyl, unsubstituted C 1~6 Alkyl, optionally substituted C6 aryl and optionally substituted C6 aryl-C 1~6 More preferably, R is selected from alkyl. 3 are independently hydroxy-substituted C 2~6 Alkyl and unsubstituted C 1~6 It is selected from alkyl, for example methyl or ethyl.

[0093] X 2 N(R 3 )2, then each R 3 may be the same or different. Each R 3 are preferably identical.

[0094] The repeating unit represented by formula (B-1) or formula (B-2) is X 2 O - When the polymer chain is anionic, it may be anionic, such as when Na + or K + may be present as a counter cation.

[0095] In the formula (B-1) or (B-2), X 2 O - , O.H., O.R. 3 , NH2 and NHR 3 More preferably, X 2 O - , O.H., O.R. 3 and NH2. 2 O - , OH and OR 3 Alternatively, X 2 O - More preferably, X is selected from the group consisting of OH and NH. 2 O - and OH.

[0096] Typically, the integer represented by n2 is at least 5, and preferably at least 10. For example, n2 may be 5-500, such as 10-300, and more preferably 15-100.

[0097] When the polymer having multiple blood-compatible groups contains a repeating unit represented by formula (A-1) (e.g., a first repeating unit) and a repeating unit represented by formula (B-1) (e.g., a second repeating unit), preferably (a) and / or (b) are applied. (a)R A is R D is different (e.g., a different group). (b)R B is R C is different (e.g., a different group).

[0098] For example, R A H and C 1~6 When selected from alkyl, R D ‐C(O)X 2 may be also possible.

[0099] In general, R B If H, then R C is C 1~6 Alkyl, preferably C 1~3 It is preferably alkyl, more preferably methyl.

[0100] Typically, the polymer having multiple hemocompatible groups is a copolymer.

[0101] The polymer having multiple blood compatible groups comprises or consists essentially of (i) a first repeat unit represented by formula (A-1) and (ii) a second repeat unit represented by formula (B-1). Thus, the polymer is a copolymer comprising or consisting essentially of (i) a first repeat unit represented by formula (A-1) and (ii) a second repeat unit represented by formula (B-1).

[0102] When the polymer having multiple blood-compatible groups is a copolymer, the copolymer may be an alternating copolymer, a random copolymer or a block copolymer. The copolymer may be an alternating copolymer. The copolymer may be a block copolymer. It is preferred that the copolymer is a random copolymer.

[0103] When the polymer having multiple hemocompatible groups is a random copolymer, the random copolymer comprises or consists essentially of (i) a first repeat unit represented by formula (A-1) and (ii) a second repeat unit represented by formula (B-1), the repeat units being randomly distributed throughout the copolymer (e.g., within the polymer chain of each copolymer molecule).

[0104] When the polymer having a plurality of blood-compatible groups is an alternating random copolymer, the alternating copolymer comprises or consists essentially of (i) a first repeat unit represented by formula (A-1) and (ii) a second repeat unit represented by formula (B-1). For example, the alternating copolymer may comprise or consist essentially of alternating first and second repeat units, preferably regularly alternating first and second repeat units (e.g., -(A-1)-(B-1)-(A-1)-(B-1)-...).

[0105] The alternating copolymer has the formula (1): -[-(A-1)-(B-1)-] n - (1) (Wherein, (A-1) is a repeating unit of formula (A-1) described herein, (B-1) is a repeat unit of formula (B-1) described herein, n is an integer greater than 0.) It may comprise or consist essentially of repeat units represented by:

[0106] When the polymer having multiple blood-compatible groups is a block copolymer, the block copolymer comprises or consists essentially of (i) a first repeat unit represented by formula (A-1) and (ii) a second repeat unit represented by formula (B-1).

[0107] For example, the block copolymer may have the formula (2): -[(A‐1)] n1 -[(B-1)] n2 - (2) (Wherein, (A-1) is a repeating unit of formula (A-1) described herein, (B-1) is a repeat unit of formula (B-1) described herein, n1 is an integer greater than 0, as described herein; n2 is an integer greater than 0, as described herein. It may comprise or consist essentially of repeat units represented by:

[0108] In one embodiment, the polymer having multiple blood compatible groups does not include a repeat unit obtained or obtainable from a maleic acid or maleimide monomer. In particular, the polymer having multiple blood compatible groups does not include a repeat unit represented by formula (A-1) as defined in claim 4 of International Publication of International Patent Application PCT / EP2020 / 081383, which is incorporated herein by reference.

[0109] Methods for making polymers with multiple hemocompatible groups are known in the art.

[0110] The coating of the present invention may further comprise a base layer, which is intended to contact or be placed on a surface of a medical device.

[0111] The base layer may be disposed on a surface of the medical device. The base layer is typically disposed directly on the surface of the medical device. Thus, the base layer is in direct contact with the surface.

[0112] Generally, it is preferred that the base layer adhere or bond, preferably adhere, to the surface of the medical device.

[0113] Typically, the base layer is biocompatible.

[0114] The base layer is typically disposed beneath the polymeric layer or surface layer.

[0115] The polymeric or surface layer is generally disposed directly on the base layer, and thus the polymeric or surface layer is typically coated onto the base layer.

[0116] Generally, the surface layer may comprise, or consist essentially of, a polymer having a plurality of hemocompatible groups, as described herein.

[0117] When the coating includes a total of two layers (eg, only two layers), the surface layer is the polymer layer. The polymer layer is disposed on the base layer.

[0118] The coating may include multiple layers disposed on a base layer. One of the multiple layers is a surface layer. In addition to the surface layer, the multiple layers may include one or more polymer layers as described herein, and / or one or more protein layers.

[0119] Generally, each protein layer comprises or consists essentially of a protein, such as a protein as described herein.

[0120] Preferably, the plurality of layers is one or more pairs of layers, each pair of layers consisting essentially of a polymer layer and a protein layer. When there is more than one pair of layers, the polymer layer from a pair of layers is preferably disposed on the base layer. The surface layer is preferably disposed on the protein layer from a pair of layers.

[0121] For example, a coating may include a base layer, a first polymer layer disposed on the base layer, a first protein layer disposed on the first polymer layer, a second polymer layer disposed on the first protein layer, a second protein layer disposed on the second polymer layer, and a surface layer disposed on the second protein layer. In this example, the first layer pair is the first polymer layer and the first protein layer. The second layer pair is the second polymer layer and the second protein layer.

[0122] Generally, the base layer comprises or consists essentially of proteins, preferably human proteins.

[0123] The protein may be albumin. Preferably, the albumin is human albumin, preferably recombinant human albumin.

[0124] Albumin, particularly recombinant human albumin, can mimic albumin found in the human circulatory system. Albumin can adhere to a wide variety of surfaces, particularly medical device surfaces, by static adsorption. It also provides a biological surface that can protect against platelet activation.

[0125] Generally, the polymer layer (or the surface layer, if there are two layers in total) is conjugated to the base layer.

[0126] When there are multiple layers, each polymer layer may be conjugated to an adjacent protein layer. A surface layer may be conjugated to a protein layer.

[0127] When a polymer layer or a surface layer is conjugated to a base layer, typically a polymer having multiple blood compatible groups (eg, from the polymer layer or the surface layer) is crosslinked to a protein (eg, from the base layer).

[0128] Similarly, when a polymer layer is conjugated to an adjacent protein layer, a polymer having multiple hemocompatible groups (eg, from the polymer layer) is crosslinked to the protein (eg, from the protein layer).

[0129] The repeating unit of formula (A-1) and / or the repeating unit of formula (B-1) may be bound, preferably cross-linked, to a protein, for example to an amino acid of a protein. It is preferred that the repeating unit of formula (B-1) is bound, preferably cross-linked, to a protein.

[0130] Conjugating the layer in this manner, typically by forming crosslinks between the polymer and the protein, is advantageous because the resulting coating is more robust. The coating can be used under acidic pH conditions without being degraded. Crosslinking also improves the adhesion of the coating to the surface of the substrate, such as when alkaline conditions are used to apply the coating.

[0131] In general, the coating may further comprise an antimicrobial agent. The base layer and / or the surface layer may comprise an antimicrobial agent. The antimicrobial agent may, for example, be mixed with components of the surface layer or the base layer.

[0132] The antimicrobial agent may include silver.

[0133] The coating of the present invention is typically disposed on a surface of a medical device. The surface of the medical device may be an inner or internal surface of the medical device (e.g., the inner surface of a catheter) or an outer surface of the medical device. The coating may be disposed on a surface of the medical device that contacts blood or blood products including platelets.

[0134] The coating may completely or partially cover the surface of the medical device.

[0135] In the coating of the present invention, the base layer is disposed on the surface of the medical device. The base layer is typically disposed directly on the surface of the medical device. Thus, the base layer is in direct contact with the surface of the medical device.

[0136] The base layer may be applied directly to the surface of the medical device, especially if it is capable of adhering or bonding to this surface.

[0137] The present invention also provides a medical device, which may be used in contact with blood or blood products containing platelets.

[0138] The coating is disposed on a surface of a medical device. Thus, the medical device has a surface coated with a coating of the present invention. For convenience, a surface coated with a coating of the present invention is referred to as a "coated surface." The coated surface is used in contact with blood or a blood product containing platelets, preferably blood.

[0139] Typically, the coating has a thickness of 0.005 μm to 300 μm, preferably 0.05 μm to 200 μm (e.g., 0.1 μm to 200 μm), more preferably 1 μm to 100 μm. Generally, the thickness of the coating is selected so as not to significantly increase the profile of the medical device for use in a patient.

[0140] The medical device may be coated with a coating that includes, or consists essentially of, a base layer and a surface layer. Alternatively, the medical device may be coated with a coating that includes multiple layers disposed on a base layer, as described herein. Thus, the surface of the medical device may be coated with multiple alternating layers of protein and polymer layers.

[0141] The medical device may be an implantable medical device or an extracorporeal medical device. The implantable medical device may be a permanently implantable medical device or a temporarily implantable medical device.

[0142] The medical device may be a temporary blood contacting device, eg, it may be neither implantable nor extracorporeal.

[0143] The medical device may be for in vivo or in vitro use. The medical device is preferably for in vivo use.

[0144] The medical device may have a component for in vivo use, preferably at least a surface of which is coated with the coating of the present invention.

[0145] The coated surface of the medical device or a component of the medical device may be inserted into an area of ​​the body, such as an affected area of ​​the body, which may be an artery or vein, such as, for example, a coronary artery or vein, a carotid artery or vein, a renal artery or vein, an iliac artery or vein, a femoral artery or vein, a popliteal artery or vein, a subclavian artery or vein, an intercranial artery or vein, an aorta, a vena cava, or a peripheral artery or vein.

[0146] Once in place, the coated surface prevents blood clotting on and around the medical device or components of the medical device, thereby inhibiting thrombosis, particularly subacute device thrombosis.

[0147] A medical device or component thereof may be a needle, catheter, stent, graft, shunt, dressing, surgical staple, guidewire, cannula, surgical instrument, endoscope, artificial organ or organoid (e.g., insulin secretion device), implantable monitor or sensor, defibrillator, ventricular assist device, pacemaker (e.g., cardiac pacemaker), implantable pump (e.g., intra-aortic balloon pump or ventricular assist pump), cell reservoir (e.g., for stem cell transplantation), prosthetic device (such as artificial heart valve), orthopedic device, electrical The device may be a blood stimulation lead or lead tip, an implantable vascular access port, a blood storage bag, a blood tube, a breast implant, a pain management device, a prostate cancer treatment device, a dental implant, a localized epilepsy treatment device, a nerve regeneration conduit, a vena cava filter, a spinal cord repair device, a spinal cord stimulator, an internal hearing aid, a neuroaneurysm treatment device, a heart valve repair device, an intravitreal drug delivery device, an artificial joint, an ophthalmic implant, a blood oxygenator, a blood filter, a septal defect device, a hemodialysis device, a hemoperfusion device, a plasma exchange device or an anastomosis device.

[0148] Examples of catheters include balloon or dilatation catheters, injection catheters, central venous catheters, arterial catheters, suction catheters. It may be preferred that the medical device is a central venous catheter or a suction catheter.

[0149] Examples of grafts include vascular grafts, stent grafts, and bypass grafts. It may be preferred that the medical device is a bypass graft.

[0150] Examples of stents include vascular stents, urethral stents, biliary stents, biliary stents, esophageal stents, tracheal or bronchial stents.

[0151] Generally, the medical device is preferably selected from central venous catheters, suction catheters, bypass grafts, perfusion lines, cardiac bypass machines, and extracorporeal oxygenation and heat exchange circuits.

[0152] The medical device or component thereof may comprise a metal, a polymeric material, a glass or a ceramic. Thus, the coating of the present invention may be applied to surfaces comprising metals, plastics or ceramics.

[0153] The metal may be, for example, stainless steel, titanium, nickel, tantalum, cobalt, chromium, nickel, molybdenum, manganese, gold, platinum, iridium, silver, tungsten, titanium alloys (e.g., Nitinol), nickel-chromium alloys (e.g., Inconel), cobalt-chromium alloys (e.g., Elgiloy), iron alloys, palladium alloys, rhenium alloys, or magnesium alloys.

[0154] The polymeric material may be, for example, cellulose acetate, cellulose nitrate, silicone, polyethylene terephthalate, polyurethane, polyamide, polyester (eg, Nylon), polyorthoester, polyanhydride, polyethersulfone, polycarbonate, polypropylene, polyethylene, or polytetrafluoroethylene.

[0155] The ceramic may include, for example, transition metal oxides, carbides, or nitrides, such as titanium oxide, hafnium oxide, iridium oxide, chromium oxide, aluminum oxide, zirconium oxide, and the like.

[0156] The present invention also provides a method for producing a coating for a medical device. The present invention also relates to a coating obtained or obtainable from this method.

[0157] One aspect of the present invention is a method of coating the surface of a medical device. The method is a method of producing a coating for a medical device that is performed on the surface of the medical device.

[0158] Typically, the method includes (a) applying a polymer having a plurality of hemocompatible groups as described herein onto a base layer (e.g., onto a base layer on the surface of a medical device). The polymer is applied onto the base layer to form a layer (e.g., a polymer layer, or a surface layer if the coating includes only two layers).

[0159] The method of the present invention is advantageous because the polymer with multiple blood compatible groups is preformed before being applied to the base layer or protein layer. This avoids the need to functionalize the precursor polymer with blood compatible groups in situ, such as when the precursor polymer is applied onto the protein-containing layer. Forming the polymer with multiple blood compatible groups in situ when it is part of a layer limits the chemical techniques that can be used, as they may affect the protein-containing layer. This method allows a wider range of methodologies to be used to make the polymer.

[0160] The method of the present invention allows the creation of coatings having multiple layers, which can be built up layer by layer depending on the required performance and cost. The layers can also be applied to the surface of a medical device without the need for a solvent.

[0161] The method may include (a1) preparing a base layer as described herein on a surface of a medical device, and then (a2) applying a polymer having a plurality of blood-compatible groups as described herein to the base layer.

[0162] In step (a1) of the method, the base layer may be prepared, for example, by applying a base coating solution to the surface of the medical device (e.g., forming a coated surface). After applying the base coating solution to the surface of the medical device, the coated surface is dried or allowed to dry.

[0163] Generally, the base coating solution comprises a protein as described herein. The base coating solution may be an aqueous solution, preferably a buffered aqueous solution, that comprises the protein.

[0164] The base coating solution may have a pH of <7, for example a pH of about 3.5 to about 6.5, preferably a pH of about 4.0 to about 6.0.

[0165] The base coating solution may further include a protein stabilizer.

[0166] In principle, the base coating solution may be applied to the surface of the medical device using conventional techniques.

[0167] For example, the base coating solution can be applied to the surface of the medical device by, for example, dip coating, spraying, washing, brushing, rolling, wiping, or spin coating. The base coating solution can be poured onto the surface of the medical device, or the surface of the medical device can be dipped or rinsed with the base coating solution. Alternatively, the base coating solution can be pumped through the medical device to coat the interior surface of the medical device.

[0168] It is preferred that the surface of the medical device be dipped or rinsed with the base coating solution.

[0169] The thickness of the base layer may be controlled by varying the immersion time, flow rate, etc., and the number of coating steps. Each coating may be provided to the surface of the medical device, as described herein, in a series of applications. The number of applications may be selected to provide an individual coating layer of suitable thickness, and the total number of coatings desired.

[0170] The base layer is applied to the surface of the medical device before the surface layer.

[0171] Generally, step (a1) creates a base layer on the surface of the medical device.

[0172] Step (a1) may be repeated to produce a base layer. By repeating step (a1), the thickness of the base layer may be increased.

[0173] In step (a2), the polymer having a plurality of hemocompatible groups may be applied onto the base layer (e.g., to form or provide a coated base layer) by applying the polymer coating dispersion onto the base layer. After applying the polymer coating dispersion onto the base layer, the coated base layer is dried or allowed to dry.

[0174] Generally, a polymeric coating dispersion comprises a polymer having a plurality of hemocompatible groups and a liquid medium (or vehicle).

[0175] The polymer coating dispersion may be a solution or a suspension, and thus the polymer may be dissolved in the liquid medium (e.g., if the polymer coating dispersion is a solution) or suspended in the liquid medium (e.g., if the polymer coating dispersion is a suspension).

[0176] The liquid medium may be water or ethanol. Preferably, the liquid medium is water, preferably deionized water.

[0177] The polymeric coating dispersion is preferably buffered.

[0178] The polymer coating dispersion may have a pH of <7, for example a pH of about 3.5 to about 6.5, preferably a pH of about 4.0 to about 6.0.

[0179] The polymer coating dispersion may be applied onto the base layer using conventional techniques. For example, the polymer coating dispersion may be applied onto the base layer (e.g., onto the surface of the medical device) by, for example, dip coating, spraying, washing, brushing, rolling, wiping, or spin coating. The polymer coating dispersion may be poured onto the base layer, or the base layer on the surface of the medical device may be dipped into or rinsed with the polymer coating dispersion. Alternatively, the polymer coating dispersion may be pumped through the medical device to coat the base layer on the interior surface of the medical device.

[0180] It is preferred that the surface of the medical device be dipped or rinsed with the base coating solution.

[0181] The thickness of the polymer layer may be controlled by varying the immersion time, flow rate, etc., and the number of coating steps.

[0182] Preferably, the base layer (eg, on the surface of the medical device) is dipped into or rinsed with the polymer coating dispersion.

[0183] Generally, step (a2) creates a polymer layer on a protein layer such as a base layer. If the coating comprises only two layers, the polymer layer is the surface layer.

[0184] Step (a2) may be repeated to produce a polymer layer or a surface layer. By repeating step (a2), the thickness of the polymer layer or surface layer may be increased.

[0185] When the coating contains only two layers, there is a single protein layer, which is the base layer, and a single polymer layer, which is the surface layer.

[0186] The coating may include multiple protein layers (eg, including a base layer) and / or multiple polymer layers (eg, including a surface layer).

[0187] After steps (a1) and (a2), the method may further comprise (a3) ​​applying a protein layer as described herein to the polymer layer, and then (a4) applying a polymer having a plurality of blood-compatible groups as described herein to the protein layer.

[0188] In step (a3) ​​of the method, the protein layer may be prepared by applying a base coating solution described herein to the polymer layer (e.g., to form a coated polymer layer surface). After applying the base coating solution to the polymer layer, the coated polymer layer surface is dried or allowed to dry.

[0189] Step (a3) ​​may be carried out in the same manner as step (a1). Thus, the base coating solution may be applied to the polymer layer in the same way that a base coating solution is applied to the surface of a medical device.

[0190] Generally, step (a3) ​​produces a protein layer on a polymer layer.

[0191] Step (a3) ​​may be repeated (e.g. before carrying out step (a4)) to produce a protein layer. By repeating step (a3), the thickness of the protein layer may be increased.

[0192] In step (a4), the polymer having a plurality of hemocompatible groups may be applied onto the protein layer by applying a polymer coating dispersion as described herein onto the protein layer (e.g., to form or provide a coated protein layer). After applying the polymer coating dispersion onto the protein layer, the coated protein layer is dried or allowed to dry.

[0193] Step (a4) may be carried out in a similar manner to step (a2). Thus, the polymer coating dispersion may be applied to the protein layer in the same way that the polymer coating dispersion is applied to the base layer.

[0194] Generally, step (a4) produces a polymer layer on a protein layer.

[0195] Step (a4) may be repeated to produce a polymer layer. By repeating step (a4), the thickness of the polymer layer may be increased.

[0196] Both steps (a3) ​​and (a4) may be performed once or repeatedly. It may be preferred to perform both steps (a3) ​​and (a4) once, twice or three times.

[0197] By carrying out steps (a3) ​​and (a4), a coating having multiple layers, one or more sets of layers, may be produced, where each set of layers consists essentially of a polymer layer and a protein layer.

[0198] If step (a4) is finally carried out, the resulting polymer layer is a surface layer.

[0199] In general, the method of the present invention includes (b) coupling a polymer having a plurality of blood-compatible groups to a protein with a coupling agent. Coupling the polymer to the protein preferably involves crosslinking the polymer to the protein.

[0200] The polymer may be crosslinked to the protein by forming an amide bond between the polymer and the protein. For example, a carboxylic acid, ester or amide in the repeat unit of formula (B-1) may form an amide bond with an amino acid in the protein.

[0201] Typically the coupling agent is a carbodiimide coupling agent. Carbodiimide coupling agents are known in the art.

[0202] The carbodiimide coupling agent may be selected from N,N'-dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIC) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). It is preferred that the carbodiimide coupling agent is EDC.

[0203] In step (b) of the method, attaching the polymer having multiple blood compatible groups to the protein with a coupling agent may be by applying a coupling agent solution to a coating comprising a protein layer as described herein and a polymer layer as described herein, wherein the protein layer comprises a protein and the polymer layer comprises a polymer having multiple blood compatible groups.

[0204] The coupling agent may be applied to a surface layer of the coating.

[0205] Typically, the polymer layer is a surface layer.

[0206] The protein layer may or may not be a base layer.

[0207] Generally, the coupling agent solution comprises a coupling agent as described herein, such as a carbodiimide coupling agent.

[0208] The coupling agent solution may be an aqueous solution, preferably a buffered aqueous solution.

[0209] In principle, the coupling agent solution may be applied to the coating using conventional techniques.

[0210] The coupling agent solution may be applied onto the base layer using conventional techniques. For example, the coupling agent solution may be applied to a polymer layer (e.g., the surface of a medical device), such as a surface layer, by dip coating, spraying, washing, brushing, rolling, wiping, or spin coating. The coupling agent solution may be poured onto the polymer layer (e.g., the surface layer), and the surface of the medical device may be immersed in or rinsed with the coupling agent solution. Alternatively, the coupling agent solution may be pumped through the medical device to coat the polymer layer (e.g., the surface layer) on the interior surface of the medical device.

[0211] The coating is preferably dipped into or rinsed with the coupling agent solution.

[0212] Generally, step (b) is performed to produce a crosslinked coating on the surface of the medical device. Prior to application of the coupling agent, the coating on the surface of the medical device is usually non-crosslinked (i.e., a polymer layer, such as a surface layer, is not coupled to a protein layer, such as a base layer).

[0213] Step (b) may involve repeated application of a coupling agent solution to the coating comprising the protein layer and the polymer layer, which may ensure sufficient cross-linking within the coating.

[0214] In the method of the invention, step (b) may be carried out directly after step (a), for example after steps (a1) and (a2). Additionally or alternatively, step (b) may be carried out after steps (a3) ​​and (a4).

[0215] Step (b) may be performed after each repetition of steps (a3) ​​and (a4), or step (b) may be performed after all repetitions of steps (a3) ​​and (a4) have been performed.

[0216] Typically, step (b) is the final step in the method (eg the final step involving application of the solution).

[0217] Any remaining coupling agent solution can be removed, such as by rinsing with water.

[0218] Generally, it is preferred that step (b) is performed only after a surface layer (e.g., a surface layer of a non-crosslinked coating) has been applied. Thus, once the layer has been applied to the surface of the medical device, a single bonding step is performed.

[0219] Another general feature of the methods of the invention is that step (a) may include preparing a polymer having a plurality of hemocompatible groups.

[0220] The polymer having a plurality of blood compatible groups is represented by (i) formula (a-1): TIFF2024520221000007.tif41147 (in the formula, R A , R B and X 1 is as described herein in relation to the repeat unit of formula (A-1). It may be prepared by polymerizing monomers of the formula:

[0221] The monomer of formula (a-1) may preferably be 2-acrylamido-2-methyl-1-propanesulfonic acid (AMPS), 3-(acryloyloxy)propane-1-sulfonic acid or 3-(methacryloyloxy)propane-1-sulfonic acid. It is preferred that the monomer of formula (a-1) is 2-acrylamido-2-methyl-1-propanesulfonic acid (AMPS).

[0222] A polymer having multiple blood compatible groups can be prepared by (i) converting a monomer of formula (a-1) described herein into a monomer of formula (b-1) or (b-2): TIFF2024520221000008.tif47150 (in the formula, R C , R D and X 2is as described herein in relation to the repeat unit of formula (B-1); and X 3 are O, NH and NR 3 where R 3 is as defined herein. 3 is preferably selected from O and NH, more preferably X 3 is O.) Preferably, it is prepared by copolymerizing with a monomer of

[0223] The monomer of formula (b-1) may preferably be acrylic acid, methacrylic acid, an ester of acrylic acid, an ester of methacrylic acid, an amide of acrylic acid, an amide of methacrylic acid, maleic acid or an ester or amide thereof. The ester of methacrylic acid may be 2-hydroxyethyl methacrylate (HEMA) or 2-hydroxypropyl methacrylate. The monomer of formula (b-2) may be maleic anhydride or a maleimide.

[0224] The polymer having multiple hemocompatible groups is preferably prepared by (i) copolymerizing a monomer of formula (a-1) described herein with a monomer of formula (b-1).

[0225] Typically the copolymerization is a free radical copolymerization.

[0226] The copolymerization, particularly the free radical copolymerization, may be carried out using methods known to those skilled in the art.

[0227] In (i), the copolymerization of the monomer of formula (a-1) with the monomer of formula (b-1) or (b-2) is carried out using a copolymerization catalyst.

[0228] When the copolymerization is a free radical copolymerization, the copolymerization catalyst may be a free radical initiator.

[0229] The free radical initiator may be any free radical initiator suitable for copolymerization of monomers. The free radical initiator is preferably non-toxic to humans and preferably biocompatible.

[0230] The free radical initiator may be, for example, a thermal initiator, a photoinitiator, a photocationic initiator, or a photoanionic initiator.

[0231] The thermal polymerization initiator may be an organic peroxide, an azo compound or a persulfate.

[0232] When the thermal polymerization initiator is an organic peroxide, the organic peroxide may be selected from tert-butyl hydroperoxide (TBHP), cumene hydroperoxide, di-tert-butyl hydroperoxide, dicumyl peroxide and benzoyl peroxide (BPO).

[0233] When the thermal polymerization initiator is an azo compound, the azo compound can be selected from azoisobutylnitrile (AIBN) and 2,2'-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride. It is preferred that the thermal polymerization initiator is azoisobutylnitrile (AIBN).

[0234] When the thermal polymerization initiator is a persulfate, the persulfate may be selected from ammonium persulfate (also known as ammonium peroxydisulfate), sodium persulfate and potassium persulfate. It is preferred that the persulfate is ammonium persulfate.

[0235] Examples of photopolymerization initiators include (±)-camphorquinone, acetophenone, 4'-hydroxyacetophenone, 3'-hydroxyacetophenone, benzophenone, 3-methylbenzophenone, 2-methylbenzophenone, 3,4-dimethylbenzophenone, 3-hydroxybenzophenone, 4-hydroxyphenone, 4,4'-dihydroxybenzophenone, 4-benzoylbenzoic acid, 2-benzoylbenzoic acid, methyl 2-benzoylbenzoate, 4, 4'-Carbonyldiphthalic anhydride, 4-(dimethylamino)benzophenone, 4,4'-bis(dimethylamino)benzophenone, 4,4'-bis(diethylamino)benzophenone, 4,4'-dichlorobenzophenone, 4-phenylbenzophenone, 1,4-dibenzoylbenzene, 4-(p-tolylthio)benzophenone, dibenzosuberenone, benzyl, p-anisyl, methyl benzoylformate, 9,10-phenanthrenequinone, 2-benzyl benzoyl-2-propanol, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone, 1-benzoylcyclohexanol, benzoin, anisoin, benzoin methyl ether, benzoin ethyl ether, benzoin isopropyl ether, benzoin isobutyl ether, 2,2-diethoxyacetophenone, benzil dimethyl ketal, 2-methyl-4'-(methylthio)-2-morpholinopropiophenone, These include 2-benzyl-2-(dimethylamino)-4'-morpholinobutyrophenone, 2-isonitrosopropiophenone, 9,10-phenanthrenequinone, 2-ethylanthraquinone, sodium anthraquinone-2-sulfonate monohydrate, 2-chlorothioxanthone, 1-chloro-4-propoxythioxanthone, 2-isopropylthioxanthone, 2,4-diethylthioxanthone-9-one and 2,7-dimethoxythioxanthone.

[0236] Examples of photocationic initiators include diphenyliodonium trifluoromethanesulfonate, diphenyliodonium hexafluoroarsenate, diphenyliodonium hexafluorophosphate, triphenylsulfonium bromide, triphenylsulfonium tetrafluoroborate, triphenylsulfonium nonaflate, tri-p-tolylsulfonium triflate, tri-p-tolylsulfonium hexafluorophosphate, 4-nitrobenzenediazonium tetrafluoroborate, 2-(4-methylphenyl)-2-propanediol ... 2-(1,3-benzodioxol-5-yl)-4,6-bis(trichloromethyl)-1,3,5-triazine, 2-(4-methoxystyryl)-4,6-bis(trichloromethyl)-1,3,5-triazine, 2-(3,4-dimethoxystyryl)-4,6-bis(trichloromethyl)-1,3,5-triazine and 2-[2-(furan-2-yl)vinyl]-4,6-bis(trichloromethyl)-1,3,5-triazine.

[0237] Examples of photoanionic initiators include acetophenone O-benzoyloxime, 2-nitrobenzylcyclohexylcarbamate, 1,2-bis(4-methoxyphenyl)-2-oxoethylcyclohexylcarbamate, 1-(2-formylbenzoyl)piperidine, and nifedipine.

[0238] Generally, it is preferred that the free radical initiator be a thermal polymerization initiator such as an azo compound or a persulfate.

[0239] The present invention also provides a kit for coating a medical device, the kit including (a) a polymer having a plurality of hemocompatible groups as described herein, (b) a base coating solution as described herein, and (c) a coupling agent.

[0240] The kit preferably comprises (a) a polymeric coating dispersion as described herein that includes a polymer having a plurality of hemocompatible groups.

[0241] Additionally or alternatively, the kit preferably includes (c) a coupling agent solution, as described herein, that includes a coupling agent.

[0242] Generally, the kit may also include (d) instructions for producing a coating on the surface of the medical device.

[0243] The present invention also provides uses of the coatings and medical devices.

[0244] The coatings or medical devices comprising the coatings may be used in the treatment of the human or animal body by surgery or therapy and / or in diagnostic methods performed on the human or animal body.

[0245] Diagnostic methods which are performed on the human or animal body are typically in vivo diagnostic methods.

[0246] Diagnostic methods or surgical or therapeutic procedures typically involve contacting the coating or a medical device containing the coating with blood.

[0247] The coating or medical device including the coating is used to reduce or prevent blood clotting, preferably on the coated surface of the medical device.

[0248] The invention also provides a method of reducing or preventing blood clotting, the method comprising contacting a medical device of the invention with blood, the medical device being used in the normal manner, except that the presence of the coating inhibits or prevents the formation of thrombi, particularly on the coated surface of the medical device.

[0249] One embodiment of the method is an in vitro method.For example, the method may be an in vitro method for reducing or preventing blood clotting during blood processing.Blood can be processed to produce processed blood or blood products, such as blood products for storage.

[0250] The method may include contacting the medical device with blood, the blood having been removed from a human or animal body. The blood may be contacted with the medical device to treat the blood.

[0251] The method may not include a step of administering the treated blood or blood product to a human or animal body. The blood product or treated blood may not be returned to the human or animal body, preferably the human or animal body from which the blood was removed.

[0252] A further embodiment of the method is a diagnostic method, in particular an in vitro and / or ex vivo diagnostic method.

[0253] The method may relate to a method of reducing or preventing clotting of blood in a diagnostic procedure. The method may include contacting a medical device with blood to obtain diagnostic information. The medical device may be contacted with pre-obtained or pre-delivered blood.

[0254] The diagnostic procedure is not performed on a human or animal body, or the diagnostic procedure is performed on a non-living (e.g. cadaveric) human or animal body. Thus, the diagnostic method may not include a step of removing blood from a human or animal body, particularly a living human or animal body. EXAMPLES

[0255] The invention is illustrated by the following non-limiting examples.

[0256] Preparation of AMPS-MAA copolymer A round bottom flask equipped with a magnetic stir bar was charged with 2-acrylamido-2-methylpropanesulfonic acid (AMPS), deionized (DI) water, methacrylic acid (MAA) and azoisobutyronitrile (AIBN). The amounts of each component used are shown in Table 1 below.

[0257] The solution was stirred vigorously to dissolve the AMPS. A condenser (with bubbler) was attached and the mixture was sparged with nitrogen for 30 minutes. The nitrogen sparge was changed to a nitrogen sweep and the mixture was heated to 70° C. for 24 hours. As the polymerization proceeded, the mixture took on a slightly hazy appearance. The mixture was cooled and drained to give a slightly hazy, medium viscous solution. JPEG2024520221000009.jpg76164

[0258] Analysis data Characterization data for each batch is shown below in Table 2. For NMR data, peak intensities are shown in bold. JPEG2024520221000010.jpg112164

[0259] Recombinant Human Albumin Coating A solution of recombinant human albumin (Albumedix®) was made in distilled water in a pure buffer of pH 4.0-4.5 (by HCl and NaOH titration) to give a concentration of albumin in solution of approximately 0.05 g / 2000 mL.

[0260] The PVC tubing samples were washed or suspended in albumin solution for 20 minutes at room temperature to produce human albumin-coated samples.

[0261] All albumin-coated samples were then washed with pure water for 10 min or immersed in pure water and then dried.

[0262] Coating with AMPS-MAA copolymer A solution of AMPS-MAA copolymer from Batch No. 4 above was made at a concentration of 0.2 mL per 1000 mL using pure water buffer at pH 4.0-4.5 (by HCl and NaOH titration).

[0263] The human albumin-coated samples were washed with or soaked in a solution of AMPS-MAA copolymer for 20 minutes.

[0264] After applying the AMPS-MAA copolymer coating, the coated samples were washed with pure water for 10 min or immersed in pure water and then dried.

[0265] Crosslinking of coatings Solutions of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) were made in pure water buffers of pH 5.0-5.5 (by HCl and NaOH titration) to a concentration of 75 mg EDC per 1000 mL.

[0266] The coated samples were washed with EDC solution for 20 min. After washing with EDC solution, the samples were washed with pure water for 30 min and dried.

[0267] Coating Samples Using the albumin and copolymer coating process described above, two sets of samples were prepared: The first set of samples had a single coating of human albumin and AMPS-MAA copolymer prepared as described above.

[0268] A second set of samples was prepared that was triple-coated with both albumin and copolymer layers, and the above steps of applying an albumin coating followed by a copolymer coating were repeated a total of three times for the second set of samples.

[0269] Both the first and second sets of samples were treated with toluidine blue, which has a high affinity for acidic groups, such as sulfonic acid groups, present in the coating. After treatment, the coated samples showed a pink color, confirming the presence of sulfonic acid groups.

Claims

1. A base layer containing a protein, and A polymer layer disposed on the base layer comprising The polymer layer contains a polymer having a plurality of blood compatibility groups, and each blood compatibility group is independently selected from a sulfonic acid group, a sulfonamide group, a sulfamic acid group, a hydrogen sulfate group, and their conjugate bases, a coating for a medical device.

2. The coating according to claim 1, wherein the polymer layer is conjugated to the base layer.

3. The coating according to claim 1, wherein the protein is albumin, preferably human albumin.

4. The coating according to claim 1, wherein each blood compatibility group is selected from a sulfonic acid group or a sulfonate group.

5. A polymer having a plurality of blood compatibility groups has the formula (A-1): [wherein, R Ａ is selected from H and C １～６ alkyl, R Ｂ is selected from H and C １～６ alkyl, X １ is the formula (S-1): -Z １ -L １ -SO ２ -Y １ (S-1) represented by In formula (S-1), Z １ is selected from O, NH, and NR １ and R １ is selected from C １～６ alkyl, C ６～１０ aryl and C ６～１０ aryl C １～６ alkyl, Y １ is selected from O － , OH, NH － and NH ２ and is selected from L １ is given by formula (L-1): -P １ -Q １ -W １ (L-1) represented by In formula (L-1), P １ is selected from a single bond, C １～１０ alkylene, C ２～１０ alkenylene, C ２～１０ alkynylene and phenylene, Q １ is selected from single bond, O, NH, NR ２ and phenylene, W １ is selected from a single bond, C １～１０ alkylene, C ２～１０ alkenylene, C ２～１０ alkynylene and phenylene, R ２ is selected from C １～６ alkyl, C ６～１０ aryl and C ６～１０ aryl C １～６ alkyl.] The coating according to claim 1, comprising a repeating unit represented by

6. (a) R Ａ is selected from hydrogen and methyl, preferably R Ａ is hydrogen, and / or (b) RB is selected from H and methyl, preferably RB is hydrogen, the coating according to claim 5.

7. (a) Z １ is selected from O and NH, preferably Z １ is NH, and / or (b) Y1 is selected from O− and OH, the coating according to claim 5.

8. (a) P １ is C １～１０ alkylene, C ２～１０ alkenylene and C ２～１０ alkynylene selected from; Q １ is a single bond, W １ is a single bond, preferably P １ is C １～１０ alkylene, optionally C ２～６ alkylene, more preferably P １ is isobutylene, or (b) P1 is selected from C1-10 alkylene, C2-10 alkenylene and C2-10 alkynylene, Q1 is selected from О, NH and NR2, and W1 is a single bond, preferably Q1 is selected from O and NH, the coating according to claim 5.

9. A polymer having a plurality of blood compatibility groups has the formula (B-1): [wherein, R Ｃ is selected from H and C １～６ alkyl, R Ｄ is selected from H, C １～６ alkyl and -C(O)X ２ and is selected from Each X ２ is independently O, OH, OR ３ , NH ２ , NHR ３ and N(R ３ ) ２ is selected from; and Each R ３ is independently selected from optionally substituted C １～６ alkyl, optionally substituted C ６～１０ aryl and optionally substituted C ６～１０ aryl C １～６ alkyl.] The coating according to claim 1, comprising a repeating unit represented by:

10. (a) R Ｃ is selected from H and methyl, preferably R Ｃ is methyl, and / or (b) RD is selected from H and methyl, preferably RD is hydrogen, and / or (c) X2 is selected from O− and OH, the coating according to claim 9.

11. The coating according to claim 1, wherein the polymer having a plurality of blood compatibility groups is a copolymer.

12. A medical device having a surface coated with the coating according to any one of claims 1 to 11.

13. A method for manufacturing a coating for a medical device according to any one of claims 1 to 11, comprising: (a) applying a polymer having a plurality of blood compatibility groups to a base layer to form a polymer layer comprising Each blood compatibility group is independently selected from a sulfonic acid group, a sulfonamide group, a sulfamic acid group, a hydrogen sulfate group and their conjugate bases, and the base layer contains a protein, and optionally (b) coupling a polymer having a plurality of blood compatibility groups to a protein using a coupling agent comprising, preferably, the coupling agent being a carbodiimide cross-coupling agent.

14. The coating according to any one of claims 1 to 11 for use in the treatment of the human or animal body by surgery or therapy and / or in a diagnostic method carried out on the human or animal body.

15. The medical device according to claim 12 for use in the treatment of the human or animal body by surgery or therapy and / or in a diagnostic method carried out on the human or animal body.

16. The coating according to any one of claims 1 to 11 for use in reducing or preventing blood clotting.

17. The medical device according to claim 12 for use in reducing or preventing blood clotting.